Skip to content

Aurinia Pharmaceuticals AUPH Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Rogers Corporation logo
Rogers CorporationROG
$14.7M-9.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.86M
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$42M+145%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$90K-89.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$229K-34.9%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$25.32M+393%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's other non-current liabilities?
Aurinia Pharmaceuticals (AUPH) reported other non-current liabilities of $6.9M in Q1 2026.
How has Aurinia Pharmaceuticals's other non-current liabilities changed year-over-year?
Aurinia Pharmaceuticals's other non-current liabilities decreased by 39.5% year-over-year, from $11.4M to $6.9M.
What is the long-term trend for Aurinia Pharmaceuticals's other non-current liabilities?
Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's other non-current liabilities has grown at a -16.3% compound annual growth rate (CAGR), from $16.3M to $6.7M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.